Effect of Ultra-Micronized Palmitoylethanolamide and Luteolin on Olfaction and Memory in Patients with Long COVID: Results of a Longitudinal Study
Open-label, no control groupHumansWith luteolin
This study tested palmitoylethanolamide together with luteolin. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.
- Design
- Open-label, no control group
- Subjects
- 69 patients with long COVID, in three treatment groups
- Dose used in the study
- 700 mg of palmitoylethanolamide with 70 mg of luteolin a day, taken under the tongue (Glialia). Two of the three groups also did olfactory training.
- Duration
- 90 days
- What was measured
- Odour identification scores, distorted smell (parosmia) and self-reported mental clouding
What the authors reported
Odour identification improved by an average of 10.7 points at 3 months (p < 0.0001), with improvements in parosmia and in mental clouding. There were no significant differences between the three groups at the end of the study.
Limits of this study
There was no untreated control group, so recovery over time cannot be separated from the treatment. Groups were unequal in size. Some measures were subjective. The authors name these limits. The study received no external funding.
Source
Entry checked against the full text at the publisher (MDPI) on 2026-09-21. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.